Cancer Research Meeting Calendar  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Amara, N.
Right arrow Articles by Reiter, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Amara, N.
Right arrow Articles by Reiter, R. E.
[Cancer Research 61, 4660-4665, June 15, 2001]
© 2001 American Association for Cancer Research


Advances in Brief

Prostate Stem Cell Antigen Is Overexpressed in Human Transitional Cell Carcinoma1

Nordine Amara2, Ganesh S. Palapattu2, Matthew Schrage, Zhennan Gu, George V. Thomas, Fred Dorey, Jonathan Said and Robert E. Reiter3

Departments of Urology [N. A., G. S. P., Z. G., R. E. R.], Pathology [M. S., G. V. T., J. S.], and Orthopedics [F. D.], and Jonsson Cancer Center [N. A., G. S. P., Z. G., R. E. R.], University of California-Los Angeles School of Medicine, Los Angeles, California 90095

Prostate stem cell antigen (PSCA), a homologue of the Ly-6/Thy-1 family of cell surface antigens, is expressed by a majority of human prostate cancers and is a promising target for prostate cancer immunotherapy. In addition to its expression in normal and malignant prostate, we recently reported that PSCA is expressed at low levels in the transitional epithelium of normal bladder. In the present study, we compared the expression of PSCA in normal and malignant urothelial tissues to assess its potential as an immunotherapeutic target in transitional cell carcinoma (TCC). Immunohistochemical analysis of PSCA protein expression was performed on tissue sections from 32 normal bladder specimens, as well as 11 cases of low-grade transitional cell dysplasia, 21 cases of carcinoma in situ (CIS), 38 superficial transitional cell tumors (STCC, stages Ta-T1), 65 muscle-invasive TCCs (ITCCs, stages T2-T4), and 7 bladder cancer metastases. The level of PSCA protein expression was scored semiquantitatively by assessing both the intensity and frequency (i.e., percentage of positive tumor cells) of staining. We also examined PSCA mRNA expression in a representative sample of normal and malignant human transitional cell tissues. In normal bladder, PSCA immunostaining was weak and confined almost exclusively to the superficial umbrella cell layer. Staining in CIS and STCC was more intense and uniform than that seen in normal bladder epithelium (P < 0.001), with staining detected in 21 (100%) of 21 cases of CIS and 37 (97%) of 38 superficial tumors. PSCA protein was also detected in 42 (65%) of 65 of muscle-invasive and 4 (57%) of 7 metastatic cancers, with the highest levels of PSCA expression (i.e., moderate-strong staining in >50% of tumor cells) seen in 32% of invasive and 43% of metastatic samples. Higher levels of PSCA expression correlated with increasing tumor grade for both STCCs and ITCCs (P < 0.001). Northern blot analysis confirmed the immunohistochemical data, showing a dramatic increase in PSCA mRNA expression in two of five muscle-invasive transitional cell tumors when compared with normal samples. Confocal microscopy demonstrated that PSCA expression in TCC is confined to the cell surface. These data demonstrate that PSCA is overexpressed in a majority of human TCCs, particularly CIS and superficial tumors, and may be a useful target for bladder cancer diagnosis and therapy.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
J. F. Mushinski, P. Nguyen, L. M. Stevens, C. Khanna, S. Lee, E. J. Chung, M.-J. Lee, Y. S. Kim, W. M. Linehan, M. A. Horisberger, et al.
Inhibition of Tumor Cell Motility by the Interferon-inducible GTPase MxA
J. Biol. Chem., May 29, 2009; 284(22): 15206 - 15214.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. V. Leyton, T. Olafsen, E. J. Lepin, S. Hahm, K. B. Bauer, R. E. Reiter, and A. M. Wu
Humanized Radioiodinated Minibody For Imaging of Prostate Stem Cell Antigen-Expressing Tumors
Clin. Cancer Res., November 15, 2008; 14(22): 7488 - 7496.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Z. Gu, J. Yamashiro, E. Kono, and R. E. Reiter
Anti-Prostate Stem Cell Antigen Monoclonal Antibody 1G8 Induces Cell Death In vitro and Inhibits Tumor Growth In vivo via a Fc-Independent Mechanism
Cancer Res., October 15, 2005; 65(20): 9495 - 9500.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
T. Nakamoto, H. Okada, T. Nakajima, A. Ikuta, K. Yasuda, and H. Kanzaki
Progesterone induces the fibulin-1 expression in human endometrial stromal cells
Hum. Reprod., June 1, 2005; 20(6): 1447 - 1455.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. S. Lam, J. Yamashiro, I. P. Shintaku, R. L. Vessella, R. B. Jenkins, S. Horvath, J. W. Said, and R. E. Reiter
Prostate Stem Cell Antigen Is Overexpressed in Prostate Cancer Metastases
Clin. Cancer Res., April 1, 2005; 11(7): 2591 - 2596.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
Z. Zhigang and S. Wenlv
Prostate Stem Cell Antigen (PSCA) Expression in Human Prostate Cancer Tissues: Implications for Prostate Carcinogenesis and Progression of Prostate Cancer
Jpn. J. Clin. Oncol., July 1, 2004; 34(7): 414 - 419.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
J. P.T. Higgins, L. Wang, N. Kambham, K. Montgomery, V. Mason, S. U. Vogelmann, K. V. Lemley, P. O. Brown, J. D. Brooks, and M. van de Rijn
Gene Expression in the Normal Adult Human Kidney Assessed by Complementary DNA Microarray
Mol. Biol. Cell, February 1, 2004; 15(2): 649 - 656.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
A. Jain, A. Lam, I. Vivanco, M. F. Carey, and R. E. Reiter
Identification of an Androgen-Dependent Enhancer within the Prostate Stem Cell Antigen Gene
Mol. Endocrinol., October 1, 2002; 16(10): 2323 - 2337.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Ross, S. D. Spencer, I. Holcomb, C. Tan, J. Hongo, B. Devaux, L. Rangell, G. A. Keller, P. Schow, R. M. Steeves, et al.
Prostate Stem Cell Antigen as Therapy Target: Tissue Expression and in Vivo Efficacy of an Immunoconjugate
Cancer Res., May 1, 2002; 62(9): 2546 - 2553.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
T. Watabe, M. Lin, H. Ide, A. A. Donjacour, G. R. Cunha, O. N. Witte, and R. E. Reiter
Growth, regeneration, and tumorigenesis of the prostate activates the PSCA promoter
PNAS, January 8, 2002; 99(1): 401 - 406.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.